Clinical trials: Operable Breast Neoplasms
Breast Cancer
Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer
The study goal is to develop a new method of intraoperative lymphatic mapping with fluorescent contrast agents to improve the outcome of therapeutic breast cancer surgery.
- Trial name
- NCT01614184
- Testing
- Fluorescein
- Sponsor
- University of Utah
Breast Cancer, Surgery
Optimizing the Care Pathways of Patients Treated for Operable Breast.
This prospective, multicenter, observational study aims to explore a comprehensive approach to the care of early breast cancer patients in a regional health territory (including 1.5 million women and characterized by a breast…
- Trial name
- OPTIsoins01 (NCT02813317)
- Where
- 9 sites in France
- Volunteers
- 617 people
- Sponsor
- Institut Curie
Breast Cancer
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases.
- Trial name
- NCT00010153
- Testing
- fulvestrant, conventional surgery
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs.
- Trial name
- NCT00017095
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 39 sites in Belgium, France and 7 more
- Volunteers
- 1,856 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen…
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT02003209
- Testing
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Clinical Application of CTDNA in Operable Breast Cancer Patients
Our study aims to evaluate the possibility of clinical application of CTDNA detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or indicators of early diagnosis, therapy…
- Trial name
- NCT02797652
- Testing
- Neoadjuvant chemotherapy before surgery, Surgery followed by adjuvant chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Breast Cancer and Large Operable Breast Cancer
Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer
Randomized Controlled Trial of Neoadjuvant Progesterone and Vitamin D3 in women with Large Operable Breast Cancer and Locally Advanced Breast Cancer - A Feasibility Study Primary Progesterone Timing of surgery during the…
- Trial name
- NCT01608451
- Testing
- Cholecalciferol, Inj. Progesterone
- Where
- India
- Volunteers
- 800 people
- Sponsor
- Tata Memorial Hospital
Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
This study is being offered to patients who are post-menopausal, have breast cancer with a positive estrogen and/or progesterone hormone receptor test and are currently awaiting surgery for breast cancer.
- Trial name
- NCT01814865
- Testing
- Abiraterone Acetate, Prednisone, Aromatase Inhibitor
- Where
- 4 sites in Canada
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
The efficacy of adjuvant chemotherapy is limited in patients with a high risk of recurrence. Also, for axillary positive node patients, optimum chemotherapy regimens are still under discussion.
- Trial name
- NCT00129922
- Testing
- paclitaxel, Fluorouracil, Epirubicin
- Where
- 64 sites in Spain
- Volunteers
- 1,289 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002581
- Testing
- cyclophosphamide, fluorouracil, methotrexate
- Where
- 9 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone…
- Trial name
- NCT03969121
- Testing
- Palbociclib, Endocrine therapy
- Where
- 25 sites in Australia, Hong Kong and 3 more
- Volunteers
- 141 people
- Sponsor
- Kyoto Breast Cancer Research Network
Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
This is a phase II, single institutional study, to evaluate a novel neo-adjuvant regimen in patients with operable, HER2-negative, breast cancer.
- Trial name
- NCT02215876
- Testing
- Doxorubicin, Cyclophosphamide, Eribulin
- Where
- Singapore
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Neoadjuvant Chemotherapy
Muscle Parameters and Pathological Response in Breast Cancer Patients
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
- Trial name
- NCT06151379
- Testing
- Neoadjuvant therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 69 people
- Sponsor
- Acıbadem Atunizade Hospital
Breast Neoplasms, Carcinoma
Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer
The role of early timing of adjuvant chemotherapy was postulated to be particularly important for patients with endocrine non-responsive disease.
- Trial name
- NCT00301548
- Testing
- perioperative chemotherapy
- Volunteers
- 172 people
- Sponsor
- European Institute of Oncology
Neoplasms, Breast
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
- Trial name
- NCT00422903
- Testing
- lapatinib, letrozole
- Where
- 14 sites in Italy, Spain
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma
Single Fraction Intraoperative Radiotherapy
This clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer.
- Conditions
- Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, Stage I Breast Carcinoma, Stage II Breast Carcinoma
- Trial name
- NCT01688388
- Testing
- Intraoperative Radiotherapy
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- St. Joseph Hospital of Orange
Stage II Breast Cancer, Stage III Breast Cancer
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
- Trial name
- NCT02115152
- Testing
- fluorouracil, capecitabine, cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Primary Breast Cancer
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in…
- Trial name
- NCT01019616
- Testing
- paclitaxel/anthracycline
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- Tao OUYANG